These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12434907)

  • 1. The product development continuum: the evolution and application of the concept of comparability.
    Garnick RL
    Dev Biol (Basel); 2002; 109():3-8. PubMed ID: 12434907
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulating biotechnology licensed products.
    Hill DE
    J Parenter Sci Technol; 1989; 43(3):139-41. PubMed ID: 2732852
    [No Abstract]   [Full Text] [Related]  

  • 3. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical biotechnology: a brief historical survey.
    Bernon M; Bodelle J
    Bioprocess Technol; 1991; 13():xv-xxiii. PubMed ID: 1367128
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic and biochemical factors affecting product consistency: introduction to the issues.
    Seamon KB
    Dev Biol Stand; 1992; 76():63-7. PubMed ID: 1478357
    [No Abstract]   [Full Text] [Related]  

  • 7. Reproductive toxicity testing of therapeutic biotechnology agents.
    Henck JW; Hilbish KG; Serabian MA; Cavagnaro JA; Hendrickx AG; Agnish ND; Kung AH; Mordenti J
    Teratology; 1996 Mar; 53(3):185-95. PubMed ID: 8761886
    [No Abstract]   [Full Text] [Related]  

  • 8. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
    Zoon KC
    Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
    [No Abstract]   [Full Text] [Related]  

  • 9. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to the issues: appropriate methods of process validation.
    Scribner CL
    Dev Biol Stand; 1992; 76():213-4. PubMed ID: 1478338
    [No Abstract]   [Full Text] [Related]  

  • 11. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 12. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 13. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 14. ASTM lights the way for tissue engineered medical products standards: jump start for combination medical products that restore biological function of human tissues.
    Picciolo GL; Stocum DL
    Stand News; 2001 Jan; 29(1):30-5. PubMed ID: 11833591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are biologics? A comparative legislative, regulatory and scientific analysis.
    Korwek EL
    Food Drug Law J; 2007; 62(2):257-304. PubMed ID: 17632962
    [No Abstract]   [Full Text] [Related]  

  • 16. Compliance with Good Manufacturing Practices for facilities engaged in vector production, cell isolation, and genetic manipulations.
    Steel MP; Roessler BJ
    Curr Opin Biotechnol; 1999 Jun; 10(3):295-7. PubMed ID: 10361080
    [No Abstract]   [Full Text] [Related]  

  • 17. A testing approach based on tiny doses still awaits big results.
    Coombs A
    Nat Med; 2008 Aug; 14(8):796. PubMed ID: 18685584
    [No Abstract]   [Full Text] [Related]  

  • 18. A global view of comparability concepts.
    Petricciani J
    Dev Biol (Basel); 2002; 109():9-13. PubMed ID: 12434908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The market for follow-on biologics: how will it evolve?
    Grabowski H; Cockburn I; Long G
    Health Aff (Millwood); 2006; 25(5):1291-301. PubMed ID: 16966725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacopeial perspective in accelerating the development and availability of biologicals and biotechnological-derived products.
    Williams RL
    Dev Biol (Basel); 2002; 109():137-42. PubMed ID: 12434923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.